AcelRx Pharmaceuticals (ACRX) Trading Down 2.8%

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) traded down 2.8% on Wednesday . The stock traded as low as $1.80 and last traded at $1.85. 98,888 shares were traded during trading, a decline of 76% from the average session volume of 414,101 shares. The stock had previously closed at $1.80.

Several equities research analysts have weighed in on the company. ValuEngine cut AcelRx Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 12th. Zacks Investment Research cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 23rd. Jefferies Group cut AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 13th. Royal Bank of Canada cut their target price on AcelRx Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, October 13th. Finally, Roth Capital set a $8.00 target price on AcelRx Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $6.21.

The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71. The company has a market cap of $90.61, a P/E ratio of -1.65 and a beta of 2.64.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $2.46 million. sell-side analysts anticipate that AcelRx Pharmaceuticals Inc will post -1.06 earnings per share for the current fiscal year.

In related news, Director Mark G. Edwards purchased 30,000 shares of the stock in a transaction dated Tuesday, November 14th. The stock was bought at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the acquisition, the director now owns 150,000 shares of the company’s stock, valued at $285,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 28.10% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Perennial Advisors LLC acquired a new position in shares of AcelRx Pharmaceuticals during the third quarter worth $138,000. Virtu KCG Holdings LLC increased its holdings in shares of AcelRx Pharmaceuticals by 600.9% during the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares in the last quarter. Geller Family Office Services LLC acquired a new position in shares of AcelRx Pharmaceuticals during the third quarter worth $460,000. Finally, Goldman Sachs Group Inc. acquired a new position in shares of AcelRx Pharmaceuticals during the second quarter worth $530,000. Institutional investors own 13.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AcelRx Pharmaceuticals (ACRX) Trading Down 2.8%” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2018/02/08/acelrx-pharmaceuticals-acrx-trading-down-2-8.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply